ProQR Therapeutics N.V.
NASDAQ:PRQR · NASDAQ Global Market
+$0.21 today
Vol 1.10M · Avg 0.62M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:PRQR · Revenue to Net Income
Key Ratios
Analysis
$13.4M of revenue converted into -$45.6M of net income for the selected period. Gross margin is 87.8% and net margin is -386.3%, showing how much revenue survives after costs and taxes. EPS is $-0.44, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $15.3M -19.2% | $18.9M +190.2% | $6.5M +81.2% | $3.6M +169.2% | $1.3M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $2.6M | $0 | $0 | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $12.7M -32.9% | $18.9M +190.2% | $6.5M +81.2% | $3.6M +169.2% | $1.3M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 83.0% -17.0pp | 100.0% +0.0pp | 100.0% +0.0pp | 100.0% +0.0pp | 100.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $40.7M +12.0% | $36.4M +44.6% | $25.1M -50.6% | $50.9M +20.5% | $42.2M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $14.1M +3.4% | $13.7M -15.9% | $16.2M -12.9% | $18.7M +7.4% | $17.4M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $54.8M +11.1% | $49.4M +28.7% | $38.4M -44.2% | $68.8M +17.4% | $58.5M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $2.6M -6.0% | $2.8M +9.9% | $2.5M -0.3% | $2.5M +8.2% | $2.3M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$37.0M -53.5% | -$24.1M -0.1% | -$24.1M +57.3% | -$56.5M -2.8% | -$54.9M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -242.4% -114.8pp | -127.6% +242.3pp | -369.9% +1201.0pp | -1571.0% +2545.0pp | -4116.0% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$42.2M -38.3% | -$30.5M +4.4% | -$31.9M +51.1% | -$65.2M -13.9% | -$57.2M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -275.9% -114.7pp | -161.2% +327.9pp | -489.1% +1323.9pp | -1813.0% +2472.4pp | -4285.4% | 16.6% | 24.1% | 22.0% |
| Interest Income | $2.2M -31.1% | $3.3M +25.4% | $2.6M +2346.2% | $106.0K +2020.0% | $5.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $866.4K -19.6% | $1.1M -10.5% | $1.2M -76.5% | $5.1M +50.6% | $3.4M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $1.7M -34.2% | $2.5M -37.9% | $4.0M +285.0% | $1.1M +130.3% | -$3.5M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$40.5M -44.9% | -$28.0M -0.5% | -$27.8M +56.6% | -$64.1M -5.6% | -$60.7M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -265.1% -117.2pp | -147.9% +279.1pp | -427.0% +1356.8pp | -1783.8% +2761.7pp | -4545.5% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $18.2K +109.3% | -$197.0K -152.6% | -$78.0K -181.3% | $96.0K -17.9% | $117.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | -$40.5M -45.9% | -$27.8M +1.3% | -$28.1M +56.4% | -$64.4M -6.1% | -$60.7M | $4.9B | $4.8B | $4.7B |
| Net Margin | -265.2% -118.4pp | -146.9% +284.8pp | -431.7% +1360.9pp | -1792.5% +2757.3pp | -4549.8% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$0 -11.8% | -$0 +2.9% | -$0 +61.5% | -$1 +5.2% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$0 -11.8% | -$0 +2.9% | -$0 +61.5% | -$1 +5.2% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $105.3M +29.0% | $81.7M +0.8% | $81.0M +13.1% | $71.6M +11.6% | $64.2M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $105.3M +29.0% | $81.7M +0.8% | $81.0M +13.1% | $71.6M +11.6% | $64.2M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Capricor Therapeutics, Inc.
NASDAQ:CAPR
$1.31B
Achieve Life Sciences, Inc.
NASDAQ:ACHV
$505.60M
Allogene Therapeutics, Inc.
NASDAQ:ALLO
$490.18M
Vanda Pharmaceuticals Inc.
NASDAQ:VNDA
$349.53M
Entrada Therapeutics, Inc.
NASDAQ:TRDA
$267.47M
Editas Medicine, Inc.
NASDAQ:EDIT
$257.97M
Zura Bio Limited
NASDAQ:ZURA
$241.88M
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
$213.17M
Immutep Limited
NASDAQ:IMMP
$55.46M
Mereo BioPharma Group plc
NASDAQ:MREO
$51.40M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does PRQR generate?
ProQR Therapeutics N.V. (PRQR) reported $15.28M of revenue in fiscal 2025.
Is PRQR profitable?
ProQR Therapeutics N.V. (PRQR) reported -$40,519,110.00 of net income, with a net margin of -265.2%.
Explore More
Continue the stock analysis
Jump to another research area for this company.